152 filings
Page 5 of 8
8-K
ehu 8s0jnyv0abn
4 Dec 18
Entry into a Material Definitive Agreement
8:14am
8-K
2h8mx
1 Nov 18
Revance Releases Third Quarter 2018 Results
4:10pm
8-K
mojg9v5
11 Oct 18
Departure of Directors or Certain Officers
8:53am
8-K
qhes8u5o1r9s9alwwbyh
2 Aug 18
Results of Operations and Financial Condition
4:17pm
8-K
r0x2xi tx7t1496b3
22 Jun 18
Departure of Directors or Certain Officers
4:12pm
8-K
hgan4327o
29 May 18
Departure of Directors or Certain Officers
9:37am
8-K
yf05ajwp2l
11 May 18
Entry into a Material Definitive Agreement
4:58pm
8-K
pz13tajc4e0hwla
8 May 18
Revance Releases First Quarter 2018 Results
4:14pm
8-K
nzeoat0k12l5
19 Apr 18
Revance Investor Day Highlights New Neuroscience Indications in Development
12:00am
8-K
xafpz rrel
13 Mar 18
Entry into a Material Definitive Agreement
12:00am
8-K
xgxq7zz
28 Feb 18
Entry into a Material Definitive Agreement
12:00am
8-K
wgyseh9s1csk rks
28 Feb 18
Revance Releases Fourth Quarter and Full Year 2017 Results
12:00am
8-K
s1d vzob09b3wqos
9 Feb 18
Departure of Directors or Certain Officers
12:00am
8-K
2a3p2bzocv 6ad
8 Jan 18
Revance Announces Interim Phase 2a Results for RT002 in Treating Plantar Fasciitis
12:00am
8-K
2sv ygwbzfbyg
4 Jan 18
Revance Provides Update on Anticipated Clinical Milestones and Financial Outlook for 2018
12:00am
8-K
r8f9p58gxzx
7 Dec 17
Entry into a Material Definitive Agreement
12:00am
8-K
nw57ey68in82fqsks
5 Dec 17
Achieves6-Month Duration in Pivotal SAKURA Phase 3 Trials for Glabellar Lines
12:00am
8-K
uq31issfior7uyumw
5 Dec 17
Other Events
12:00am
8-K
gxvii j1va2y
2 Nov 17
Revance Releases Third Quarter 2017 Results
12:00am
8-K
qja4fsz
6 Sep 17
Revance Appoints Mark Foley to its Board of Directors
12:00am